LOGO
LOGO

Klothos' KLTO-202 Gets Orphan Drug Designation, NRIX Advances Lead Asset, PROK To Meet With FDA

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Here's why these stocks are up in premarket trading today.

Klotho Neurosciences Inc.'s (KLTO) novel secreted-Klotho (s-KL) promoter, gene, and delivery system (KLTO-202, or s-KL-AAV.myo) has been granted Orphan Drug Designation by the FDA for the treatment of Amyotrophic Lateral Sclerosis. The company is pioneering the development of novel, disease-modifying cell and gene therapies using a patented, secreted form of the anti-aging Klotho gene (s-KL) to transform the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. Shares are up 24% at $1.70.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.